Paul Oladimeji - Novacyt SA Group RD
| NVYTF Stock | USD 0.64 0.06 8.57% |
Insider
Paul Oladimeji is Group RD of Novacyt SA
| Phone | 33 1 39 46 51 04 |
| Web | https://www.novacyt.com |
Novacyt SA Management Efficiency
The company has return on total asset (ROA) of 0.0145 % which means that it generated a profit of $0.0145 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0198) %, meaning that it generated substantial loss on money invested by shareholders. Novacyt SA's management efficiency ratios could be used to measure how well Novacyt SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MS MS | Cytosorbents Crp | 66 | |
| Robert MD | Cytosorbents Crp | 85 | |
| Danielle Watson | Heart Test Laboratories | 42 | |
| John Wilson | Rapid Micro Biosystems | 56 | |
| Lucy Liu | Biomerica | N/A | |
| Odelya Dekel | Inspira Technologies Oxy | N/A | |
| Richard Areglado | Brainsway | 60 | |
| Pr Zangen | Brainsway | 54 | |
| MD Fisher | Aethlon Medical | 77 | |
| Rony Aloni | Inspira Technologies Oxy | N/A | |
| Harold MD | NanoVibronix | 70 | |
| M Harrison | NanoVibronix | N/A | |
| Steven MD | Aethlon Medical | 56 | |
| Dagi BenNoon | Inspira Technologies Oxy | 48 | |
| CPA CPA | Cytosorbents Crp | 67 | |
| Steven Sloan | Biomerica | 54 | |
| Daniella YeheskelyHayon | Inspira Technologies Oxy | 47 | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Aron Tendler | Brainsway | N/A | |
| Ryan Sabia | Tivic Health Systems | 37 | |
| Sunil Sawhney | Aethlon Medical | N/A | |
Management Performance
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 |
Novacyt SA Leadership Team
Elected by the shareholders, the Novacyt SA's board of directors comprises two types of representatives: Novacyt SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novacyt. The board's role is to monitor Novacyt SA's management team and ensure that shareholders' interests are well served. Novacyt SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novacyt SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Gibson, Group Controller | ||
| David Franks, Chief Officer | ||
| Grald Ulrich, Chief Devel | ||
| James McCarthy, Acting CFO | ||
| Bryan Close, Chief Officer | ||
| Wendy Karban, Group Mang | ||
| Paul Oladimeji, Group RD |
Novacyt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novacyt SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 | |||
| Profit Margin | (0.1) % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | (50.49 M) | |||
| Shares Outstanding | 70.63 M | |||
| Shares Owned By Insiders | 3.49 % | |||
| Shares Owned By Institutions | 1.60 % | |||
| Price To Earning | 0.51 X | |||
| Price To Book | 0.40 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Novacyt Pink Sheet
Novacyt SA financial ratios help investors to determine whether Novacyt Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novacyt with respect to the benefits of owning Novacyt SA security.